Clinical Research
Using Novel Technology for Developing New Ways to Deliver and Experience New Medicines
Overview
Our Pharmaceutical Medicines
CURE is conducting clinical research on a variety of active pharmaceutical ingredients (APIs), both internally and through partnerships, mostly utilizing our proprietary drug delivery platform CUREfilm®. The focus of our programs is addressing novel approaches to meaningful disease states that are either undercovered or underappreciated by larger pharmaceutical players. These areas have high barriers to entry and benefit from drug delivery expertise. Our strategy is to capture these opportunities wherever possible using the 505(b)2 regulatory pathway, which enables us to seek regulatory approval at a faster pace than other pathways.
STRATEGIC
Approach
- PRODUCT DEVELOPMENT/DRUG DELIVERY EXPERTISE
- PROPRIETARY PLATFORM TECHNOLOGY
- STRATEGIC FOCUS ON LIKELIHOOD OF SUCCESS
- ABBREVIATED REGULATORY PATHWAY – 505(b)2
- DIFFERENTIATED DOSAGE FORMS/ROUTE OF ADMIN.
- MARKET/COMMERCIALIZATION
CURE PHARMACEUTICAL
Clinical Pipeline
Formulation Development
Clinical Development
Regulatory Filing
Launch
- CUREfilm® Blue (Sildenafil Citrate) 77%
- CUREfilm® Anti-Viral 52%
- CUREfilm® Mental Health Disorders (Multiple Psychedelic Compounds) 42%
- CUREfilm® Central Nervous System Disorders 42%
- CUREfilm® Canna (THC+CBD) FOR EXTERNAL PARTNERING 52%
FOR LICENSING OPPORTUNITIES AND INDUSTRY PARTNERSHIPS
Call 516.660.9148 or email us below:
PHARMACEUTICAL
Focus Areas
Focus Area
Novel Delivery of Known APIs
Focus Area
Unmet Need Applications
Focus Area
Scheduled Compounds
CUREfilm® products
Optimized Delivery
Active ingredients in the CUREfilm® dose form can be either pre-solubilized within its matrix or encapsulated, or both for more effective absorption and/or sustained release. As oral thin films quickly dissolve, no water is required for their administration, improving patient compliance – especially among the elderly, children, and in conditions where patients have difficulty in swallowing.
Novel Delivery of APIs
Specific release profiles
Increased bioavailability
Better patient experience
Protection from degradation
enhancing stability and extending shelf life.
Our Pharmaceutical Drug Development Using Novel Delivery
CUREfilm Blue
CUREfilm Blue utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience.
STATUS:
CURE Pharmaceutical has received FDA approval for IND application for erectile dysfunction product CUREfilm Blue.
CUREfilm® Explained
Unmet Need Applications
PROGRAM ADVANTAGES
- Abbreviated pathways to regulatory approval
- Large market opportunities with reduced capital requirements
- Pairing novel drug delivery increases potential regulatory approval and patent ability
- Potential for reduced side effects with a lower dose
- Can be accomplished through partnership or in-house research teams
- These types of innovation are meaningful to patients who go overlooked in big pharma
Central Nervous System (CNS) Disease States
Our Pharmaceutical Medicines
CUREfilm® Anti-Viral
We are developing an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data.
CUREfilm® for Central Nervous System Disorders
We are developing a novel dosage form of a difficult-to-treat disease state utilizing our proprietary CUREfilm dosage form
CUREfilm® Cannabis
We are developing several cannabinoid products with optimized pharmacokinetic profiles using microCURE™ and CUREfilm® technology.
CUREfilm® Blue
We are developing several cannabinoid products with optimized pharmacokinetic profiles using microCURE and CUREfilm technology.
CUREfilm® Entheogenic Compounds
As a specialty pharmaceutical company with an FDA licensed facility, cGMP manufacturing containment suites, and Schedule 1 Drug Enforcement Agency (DEA) license, CURE Pharmaceutical is focused on advancing several entheogenic compounds (5-HT2A agonists) from product development through to FDA approval. With its patented oral thin film CureFilm™, CURE is uniquely qualified to address multiple applications of these burgeoning compounds (commonly identified as psychedelic substances) for addressing high need disease states such as Post Traumatic Stress Disorder, Addiction, Obsessive Compulsive Disorder, Depression, Anxiety and Traumatic Brain Injury.
Proprietary Pharmaceutical Drug Development Programs Seeking Industry Partnership Opportunities
Pursuing University Collaborations to Support Clinical Research for High Unmet Need Disease States
Targeting FDA Submission and Approval with Alliances toward Commercial Success
researching
Scheduled Compounds
ENDOCANNABINOID SYSTEM RESEARCH
Cannabinoid research presents a unique opportunity for CURE, having successfully proved that our novel delivery system CUREfilm® improves the bioavailability of cannabinoids in the body. Many large pharmaceutical companies are researching the potential therapeutic benefits of cannabinoids such as Tetrahydrocannabinol (THC) and cannabidiol (CBD). CURE is conducting on-going clinical research on cannabinoids, both internally and through partnerships.
Cancer Research Collaboration with Technion-Israel Institute of Technology
Researchers from CURE’s Pharmaceutical Cannabinoid Division and Technion’s Laboratory of Cancer Biology and Cannabinoid Research are working together to research and identify how varying cannabinoid compounds within cannabis strains can affect various cancer subtypes. The results of the research will be used to predict how to match a cancer subtype with an effective cannabis extract in order to optimize treatment efficacy.
